 |
|
|
| |
Population Pharmacokinetic Analysis of
Velpatasvir, a Pangenotypic HCV NS5A Inhibitor,
in Healthy and Hepatitis C Virus-Infected Subjects
|
| |
| |
Reported by Jules Levin
17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, 8-10 June 2016, Washington, DC, USA
Brian Kirby,1 Erik Mogalian,1 Yuying Gao,2 Kavitha Bhasi,1 Anita Mathias1
1Gilead Sciences, Inc., Foster City, California, USA; 2Quantitative Solutions, Inc., Menlo Park, California
|
| |
|
|
|
|
|
